Mcl-1 stabilization confers resistance to taxol in human gastric cancer

Wu Shuang; Lili Hou; Yan Zhu; Qun Li; Wanglai Hu

doi:10.18632/oncotarget.20222

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Mcl-1 stabilization confers resistance to taxol in human gastric cancer

Wu Shuang, Lili Hou, Yan Zhu, Qun Li and Wanglai Hu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:82981-82990. https://doi.org/10.18632/oncotarget.20222

Metrics: PDF 2118 views | HTML 2577 views | ?

Abstract

Wu Shuang1,*, Lili Hou2,*, Yan Zhu3,*, Qun Li1 and Wanglai Hu1

1Department of Immunology, Anhui Medical University, Hefei, China

2Department of Clinical Nutriology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

3Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

*These authors have contributed equally to this work

Correspondence to:

Wanglai Hu, email: [email protected]

Keywords: Mcl-1, PI3K/Akt, Taxol-resistance

Received: March 08, 2017 Accepted: July 26, 2017 Published: August 12, 2017

ABSTRACT

Taxol has been extensively used as an antineoplastic drug to treat human gastric cancer. However, the acquired drug resistance invariably develops and greatly limits the therapeutic efficacy of Taxol. Identification of the underlying resistance mechanisms may inform the development of new therapies of gastric cancers to Taxol treatment. Here we report that upregulation of Mcl-1 (Myeloid cell leukemia-1) confers acquired resistance to Taxol in human gastric cancer. Mcl-1 is shown to be stabilized in Taxol -resistant gastric cancer cells because of the hyper-activation of the PI3K/Akt signaling pathway. The increased Mcl-1 prevents of the permeabilization of the outer mitochondrial membrane, thereby blocking the Taxol-induced apoptosis. Furthermore, inhibition of Mcl-1 or PI3K/Akt pathway significantly reversed the resistant phenotype of Taxol-resistant human gastric cancer cells. Taken together, our findings broaden the view of PI3K/Akt pathway as an important regulator in Taxol acquired resistance, and implicate Mcl-1 as a specific therapeutic target for the treatment of Taxol-resistant human gastric cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20222

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Mcl-1 stabilization confers resistance to taxol in human gastric cancer

Abstract